TABLE 3.

Estimated antibody prevalence rates early after clinical presentation in a single acute-phase serum sample from immunocompetent individuals with primary EBV infections^a

Antigen(s)	Antibody class	Prevalence rate (%)	Methodc
Heterophile antibodies	IgM	50-85b	Agglutination, rapid tests
Viral capsid antigen	IgG	98-100	IFA, EIA, WBd
Viral capsid antigen	IgM	70-100	IFA, EIA, WB
Nuclear antigen 1	IgG	0	IFA, EIA, WB
Early antigen	IgG	60-80	IFA, EIA, WB

^aData are according to references 4, 6, 11, 20, 21, 30, and 35 and unpublished observations.

^bDepending on the age of the patient.

^cPrevalence rates strongly depend on the method (IFA, EIA, or Western blot analysis) and on the different commercially available tests (manufacturer) used for determination.

^dWB, western blot analysis.